Central nervous system (CNS) disorders are some of the most prevalent yet poorly treated illnesses. Achieving sufficient blood-brain barrier (BBB) penetration is one of the biggest challenges in the development of therapeutics for CNS disorders. For instance, according to an article published by National Center for Biotechnology Information, in January 2005, more than 98% of small molecular drugs and almost 100% of larger molecular drugs are ineffective in treating CNS diseases considering that BBB strictly limits the delivery of therapeutic agents to their target site in the CNS. BBB helps to keep homeostasis in the cerebral microenvironment by controlling exchanges of substances between the CNS and the blood and serves an important function in preventing macromolecules, infectious substances, and potential neurotoxins from entering the brain. CNS disorders are rising due to factors such as aging, stress, and, lifestyle changes.
A limited understanding of the pathophysiology underlies that most of the psychiatric disorders such as schizophrenia, major depressive disorder, or bipolar disorder are only effective in a limited proportion of the patients. Some of the CNS disorders include neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease along with various infectious diseases, psychiatric disorders, mental disorders, trauma, mood disorders, and others.
Market Dynamics
The key players are focusing on various growth strategies such as collaborations and agreements which is expected to drive the market growth during the forecast period. For instance, in July 2021, Eli Lilly and Company, an American pharmaceutical company and Banner Alzheimer's Institute announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab, a biological drug in trial to treat early symptoms of Alzheimer's disease in participants at risk for cognitive and functional decline related to Alzheimer's disease (TRAILBLAZER-ALZ 3). TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.
Key features of the study:
- This report provides an in-depth analysis of the global central nervous system disorders therapeutics market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global central nervous system disorders therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market
Detailed Segmentation:
- Global central nervous system disorders therapeutics market, By Disease Type:
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
- Global Central Nervous System Disorders Therapeutics Market, By Drug Class:
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
- Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Central Nervous System Disorders Therapeutics Market, By Region:
- North America
- By Disease Type
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
- By Drug Class
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Disease Type
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
- By Drug Class
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Disease Type
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
- By Drug Class
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Disease Type
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
- By Drug Class
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Disease Type
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
- Drug Class
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- Disease Type
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
- Drug Class
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Biogen Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- AstraZeneca Plc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Glaxosmithkline plc.
- Otsuka Pharmaceutical Co., Ltd.
- Reddy's Laboratories Ltd.
- Cipla Inc.
- Lupin Ltd
- Glenmark Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.
